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Abstract
Background: Renal cell carcinoma (RCC) associated with Xp11.2 translocation/TFE3 gene fusion (Xp11.2 RCC) is a
rare subtype of RCC which is firstly described as a distinct entity in 2004 so that clinical characteristics of Xp11.2
RCC in different gender and age are unknown. The purpose of systematic review and meta-analysis is to provide a
comprehensive assessment on them.
Methods: MEDLINE, EMBASE and Cochrane databases were searched for studies which evaluate the clinical
characteristics of Xp11.2 RCC. The literature published between July 2004 and May 2014 was searched.
Results: A total of 15 studies with 147 participants were included. The meta-analysis demonstrated that number of
patients of all age in female was higher than in male with pooled OR of 3.93(95 % CI = 1.66–9.34). However, incidence
of distant metastases (OR = 0.34, 95 % CI = 0.12–1.57) and lymphatic metastases (OR = 0.51, 95 % CI = 0.14–1.91), tumor
stage (OR = 0.85, 95 % CI = 0.34–2.15) and overall survival (OS) (OR = 0.46, 95 % CI = 0.05–4.34) between male and
female were comparable. Incidence in female was higher than in male with pooled OR of 5.13(95 % CI = 1.67–15.72) in
adults, while in children no gender-related predominance (OR = 1.19, 95 % CI = 0.38–3.72) was observed. In
addition, incidence of distant metastases (OR = 1.00, 95 % CI = 0.13–7.84) and lymphatic metastases (OR = 1.00,
95 % CI = 0.07–13.67) and tumor stage (OR = 1.94, 95 % CI = 0.20–19.03) between children and adults were
comparable. Survival curves presented comparable outcomes between male and female (P = 0.707) as well as
between children and adults (P = 0.383).
Conclusions: Female patients with Xp11.2 RCC in adults exhibit a high incidence compared to male, but not in
children. Comparable clinical characteristics including incidence of distant and lymphatic metastases, tumor
stage and prognosis is presented between male and female as well as between children and adults.
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Background
Renal cell carcinoma (RCC) associated with Xp11.2 trans-
location/TFE3 gene fusion (Xp11.2 RCC) is a rare subtype
of RCC which is delineated as a distinct entity in the 2004
World Health Organization renal tumor classification [1].
This subtype affects primarily children more than adults,
accounts for 20–40 % of pediatric RCC and 1–1.6 % of
RCC in adults [2]. In addition, Xp11.2 RCC were reported
more aggressive than other subtypes of RCC and associ-
ated with a poorer prognosis [3].
Xp11.2 RCCs are generally characterized by several
translocations on chromosome Xp11.2 resulting in a
gene fusion between TFE3 and at least 6 possible part-
ners [4]. Since these translocations are located on the X
chromosome, it seems reasonable to suggest that there
are gender differences in the clinical characteristics of
Xp11.2 RCC. However, comparative analysis regarding
the clinical course of Xp11.2 RCC between male and
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female remains controversial due to relatively rare inci-
dence [5–8]. In addition, as Xp11.2 RCC predominantly
among children and associated with a poorer prognosis,
the comparison of the prognosis between children and
adults exists as well [9]. Due to such controversy in
gender and age of Xp11.2 RCC, in this systematic re-
view and meta-analysis, we studied the clinical character-
istics of Xp11.2 RCC regarding patient demographics,
incidence of distant and lymphatic metastases, tumor
stage and prognosis in order to better define the difference
of Xp11.2 RCC between male and female as well as be-
tween children and adults.
Methods
Literature search
The present meta-analysis was conducted following the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement (accessible at http://
www.prisma-statement.org/). A computer-aided literature
search was performed in May 2014 with usage of the
Cochrane, MEDLINE, EMBASE and Science Citation
Index. An initial search strategy use keywords describing
TFE3, Xp11.2 renal cell carcinoma. The literature pub-
lished between July 2004 and May 2014 was searched
since Xp11.2 RCC was first definitely diagnosed as a dis-
tinct entity in 2004. Additional studies were searched by
reference lists from primary studies to identify any studies
missed by the electronic search strategies.
Study selection
Two authors reviewed abstracts of all candidate articles
independently and read full-text review if articles could
not be categorized based on title and abstract alone. All
articles were checked for unified inclusion criteria. Dis-
crepancies were resolved by consensus with a third au-
thor. Authors of included studies were not contacted for
additional, unreported data.
Study inclusion/exclusion criteria
Studies were included if they fulfilled the following cri-
teria: (1) Studies reported clinical parameters of patients
with Xp11.2 RCC including gender and age. (2) The
diagnosis of all patients with Xp11.2 RCC was confirmed
by immunohistochemical (IHC) assay for TFE3 com-
bined with fluorescence in-situ hybridization polyclonal
(FISH) assay or other strict criteria. When the results of
FISH assay and other molecular biology such as Reverse
Transcription - Polymerase Chain Reaction (RT-PCR)
were contradicted with IHC assay, definite diagnosis of
Xp11.2 RCC was made by genetic analysis including
FISH assay and other molecular biology. Inclusion was
not limited to randomized controlled trials (RCTs).
Studies were excluded if they were (1) performed in the
lab with animal or cell models; (2) reviews and case
reports with only one case due to one case was not
enough to compare the gender and age diference; (3)
molecular or mechanism researches. When duplicate pa-
tient populations were published from on institution, the
most recent data were used.
Quality assessment of primary
Quality of primary articles was assessed in duplicate by
independent authors. Issues such as number of case,
manner of diagnosis and study design were analyzed.
Any disagreement was dealt with consensus and discus-
sion with a third author.
Data extraction
Data extraction fields for each study included the fol-
lowing: (1) demographic data concerning patient gen-
der, age, treatment and condition during follow-up
period; (2) tumor data for different gender and age in-
cluding stage, lymphatic and distant metastases. For
age, patients was divided into children (≤ 14 years) and
adults (> 14 years). When gender-related incidences in
children and adults were studied, reference would be
excluded if only 1 patient was presented in the study.
The cases of Xp11.2 RCC would be excluded if the
lymphatic and distant metastases of tumor cannot be
determined when we studied tumor metastases and
stage. If journal articles contained insufficient informa-
tion, we attempted to contact authors to obtain missing
details. If failed, we could just present out the existing
results.
Data synthesis and analysis
The clinical data included number of Xp11.2 RCC in dif-
ferent gender and age for which tumor stage, lymphatic
metastases, distant metastases and prognosis such as
overall survival (OS) were analyzed. All above data were
recorded from original articles. The statistical software
Review Manager (Version 5.0 for Windows) was applied
to carry out all the analysis. Data regarding incidence of
Xp11.2 RCC, tumor stage, metastases and overall sur-
vival were dichotomous data which was shown as odds
ratios (ORs). For dichotomous data, when no statistically
significant heterogeneity was detected, Mantel-Haenszel
fixed-effect model was used to pool ORs with 95 % con-
fidence intervals (CIs). The heterogeneity across the
studies was investigated using a χ2-based test of homo-
geneity and evaluation of the inconsistency index (I2)
statistic. The p value less than 0.1 was considered as sta-
tistically significant heterogeneity. An I2 value > 50 %
was considered to represent substantial heterogeneity
across studies, which was the symbol of applying ran-
dom- effect model. Publication bias for each of the
pooled study groups was assessed by funnel plot if the
number of studies in group was ≥ 10.
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We also estimated the survival curves in different gen-
der and age, all of whom were treated by surgical pro-
cedure such as nephron sparing surgery (NSS) and
radical nephrectomy (RN). The probability of survival
was analyzed by the Kaplan-Meier methods within the
log-rank test. Reported p values were statistical signifi-
cance set at p < 0.05.
Results
Literature and study characteristics
As shown in Fig. 1, 15 studies [4, 10–23] with 147 sub-
jects met the inclusion criteria. All of the enrolled stud-
ies were retrospective, in which 2 of them provided all
the clinical parameters in different gender while the
other gave part of these parameters, as shown in Table 1.
None of study provided detailed information about OS
in comparison of different age while other clinical pa-
rameters were shown in Table 2. The number of studies
in the pooled group of gender-related incidence in adults
were ≥ 10, as well as patients of all ages, publication bias
of the groups were described as visual assessment of a
funnel plot in Fig. 2.
Primary outcomes
The forest plots about gender-related differences and
age-related differences were shown in Figs. 3 and 4. In
study of gender-related difference in incidence of
Xp11.2, subgroup analysis was made to learn gender-
related incidence in children and adults.
Gender
Totally, the number of included patients was 147 (n = 98
for women and n = 49 for men). We observed that I2
value was > 50 % in the group of incidence of patients of
all age in different gender (I2 statistic = 55 %, P = 0.005).
Therefore we applied random- effect model in meta-
analysis of this data. Meanwhile, no evidence for signifi-
cant publication bias was observed in this pooled group.
For other group, there was no evidence for heterogeneity
about incidence of distant (I2 statistic = 0 %, P = 0.81)
and lymphatic metastases (I2 statistic = 0 %, P = 0.83),
tumor stage (I2 statistic = 0 %, P = 0.57) and OS (I2 statis-
tic = 0 %, P = 0.51). Results of meta-analysis demon-
strated that the incidence of Xp11.2 in female was
significantly higher than in male with pooled OR of
3.93(95 % CI = 1.66–9.34). However, incidence of distant
Fig. 1 PRISMA Flow Diagram of study selection for Meta- analysis
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metastases (OR = 0.43, 95 % CI = 0.12–1.57) and lymph-
atic metastases (OR = 0.51, 95 % CI = 0.14–1.91, tumor
stage (OR = 0.85, 95 % CI = 0.34–2.15) and overall sur-
vival (OS) (OR = 0.46, 95 % CI = 0.05–4.34) between
male and female were comparable. The result of OS
consistent with analysis for clinical characteristics of
Xp11.2 RCC was confirmed by survival function (P =
0.707), as shown in Fig. 5a.
Age
A total of 132 cases of Xp11.2 from 13 studies includ-
ing 23 children (≤ 14 years) and 109 adults (> 14 years)
were pooled for analyzing the clinical characteristics
between adults and children. I2 value was > 50 % in the
group of gender-related incidence in adults (I2 statistic
= 61 %, P = 0.003) so that random- effect model was ap-
plied. According to funnel plot, there was no significant
Table 1 Clinical characteristics of included studies between male and female
Reference Number of patients Incidence of lymphatic metastases Incidence of distant metastases Stage I/II (III/IV) Overall survival
Male Female Male Female Male Female Male Female Male Female
Rao et al. [20] 9 8 1/3 0/4 1/1 0/1 2/7 4/4 – –
Hodge et al. [21] 7 12 – – – – – – – –
Altinok et al. [10] 3 3 2/3 1/3 – – 1/2 2/3 0/3 0/3
Zou et al. [22] 5 4 2/5 1/4 1/5 0/4 3/2 1/3 3/4 3/4
Hung et al. [13] 1 7 0/1 2/7 0/1 2/7 1/0 3/4 – –
Green et al. [18] 10 21 0/0 4/5 1/1 3/4 4/6 9/12 – –
Zhong et al. [16] 0 6 – – – 5/6 – – – –
Choueiri et al. [11] 3 12 – – – – – – – –
Pflueger et al. [19] 4 12 1/2 3/4 1/1 0/3 – 1/3 – –
Gaillot-Durand et al. [17] 0 2 – – – – – – – –
Zhong et al. [12] 0 4 – – – – – – – –
Klatte et al. [4] 1 1 1/1 0/1 1/1 0/1 0/1 1/0 0/1 0/1
Sukov et al. [15] 2 4 – 1/2 0/2 1/4 – – 2/2 2/4
Kim et al. [14] 4 0 – – – – – – – –
Argani et al. [23] 0 2 – – – – – – – –
Table 2 Clinical characteristics of included studies between children and adults





Children (Male/Female) Adults (Male/Female) Children Adults Children Adults Children Adults
Rao et al. [20] 3/3 6/5 0/5 1/2 0/1 1/1 0/1 0/1
Hodge et al. [21] 1/1 6/11 – – – – – –
Altinok et al. [10] 3/3 – – – – – – –
Zou et al. [22] – 5/4 – – – – – –
Hung et al. [13] – 1/7 – – – – – –
Green et al. [18] 0/2 10/19 – 4/5 1/1 4/5 1/1 14/14
Zhong et al. [16] – 0/6 – – 5/6 – –
Pflueger et al. [19] 3/2 1/10 1/1 3/5 – 0/2 – 1/1
Gaillot-Durand et al. [17] – 0/2 – – – – – –
Zhong et al. [12] – 0/4 – – – – – –
Klatte et al. [4] 1/0 0/1 1/1 0/1 1/1 0/1 0/1 1/0
Sukov et al. [15] – 2/4 – – – – – –
Kim et al. [14] 1/0 3/0 – – – – – –
Argani et al. [23] – 0/2 – – – – – –
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publication bias in this study. P value was > 0.10 in group
of gender-related incidence in children (I2 statistic = 0 %,
P = 0.63) and incidence of distant (I2 statistic = 0 %, P =
0.40) and lymphatic metastases (I2 statistic = 26 %, P =
0.26) between children and adults as well as in tumor
stage (I2 statistic = 0 %, P = 0.42). Results of meta-
analysis demonstrated that the incidence of patients in
female was significantly higher than in male with
pooled OR of 5.13(95 % CI = 1.67–15.72) in adults
while in children no gender-related predominance
(OR = 1.19, 95 % CI = 0.38–3.72) was observed. In
addition, incidence of distant metastases (OR = 1.00,
95 % CI = 0.13–7.84) and lymphatic metastases (OR =
1.00, 95 % CI = 0.07–13.67) and tumor stage (OR =
1.94, 95 % CI = 0.20–19.03) between children and
adults were comparable. The result of clinical charac-
teristics of Xp11.2 RCC was confirmed by survival
function (P = 0.383), as shown in Fig. 5b.
Discussion
Xp11.2 RCC is a rare subtype of RCC which results from
gene fusions between the transcription factor E3 (TFE3)
gene and at least 5 fusion partners including ASPL-TFE3,
PRCC-TFE3, PSF-TFE3, CLTC-TFE3, and Nono -TFE3,
whose chromosomal rearrangement is t(X;17)(p11.2;q25),
t(X;1)(p11.2;q21), t(X;1)(p11.2;p34), t(X;17)(p11.2;q23) and
inv(X)(p11.2;q12), respectively [8, 24]. Due to the transloca-
tions lead to overexpression of TFE3 protein, detection
of TFE3 protein by IHC assay is currently the most
commonly used diagnostic technique in clinical prac-
tice [25]. Gaillot-Durand et al. showed that nuclei
stained with an intensity of ++ to +++ in IHC assay
was necessary to suspect the diagnosis of Xp11.2 RCC
[17]. However, recent studies have found that the posi-
tive predictive value of positive TFE3 staining for
Xp11.2 RCC is very low as well as highly false positive
results [4, 14, 17, 18]. Definite diagnosis of Xp11.2 RCC
a
b
Fig. 2 Publication bias assessment for study of distribution of Xp11.2 RCC in male and female. Funnel plots show that there was no evidence for
significant publication bias in any of the 2 pooled groups. a patients of all ages; b patients older than 14
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should be not only made by IHC assay but also by
such strict criteria as FISH assay and other molecular
biology [4, 17]. Thus, the strength of this study is that
we first analyzed the clinical characteristics of Xp11.2
RCC with the diagnostic criteria of the combined
examination of TFE3 IHC staining and other molecu-
lar biology. In our report, 21 studies were excluded
from meta-analysis because they made the diagnosis of
only by IHC assay, which may be suspected to have





Fig. 3 Forrest plots and meta-analysis of studies showing 95 % confidence interval of male Xp11.2 RCC as compared with female Xp11.2 RCC.
Clinical characteristics are reported as follows: a Number of patients of all ages; b Incidence of distant metastases; c Incidence of lymphatic metastases;
d Tumor stage; e Overall survival (OS); f Different gender-related incidence in adults; g Different gender-related incidence in children
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Gender-related difference in incidence of Xp11.2
RCC remains controversial. Several previous studies in-
dicated a female predominance in incidence of Xp11.2
RCC [7, 8, 26], while a few reports showed a male pre-
dominance in Xp11.2 RCC [5, 22]. In addition, Altinok
et al. found the male/female ratio was equal in their
study of pediatric Xp11.2 RCC [10]. We gathered all
references which met the inclusion criteria for meta-
analysis and found that the number of patients of all
ages in female was significantly higher than that in male
with pooled OR of 3.93 (95 % CI = 1.66–9.34). To learn
gender-related incidence of Xp11.2 RCC more compre-
hensively, included patients were divided into two
groups as children (≤14 years, n = 23) and adults
(>14 years, n = 109). We found that female predomin-
ance is seen in adults (OR = 5.13, 95 % CI = 1.67–15.72)
and no gender difference in children (OR = 1.19, 95 %
CI = 0.38–3.72). Although incidence of Xp11.2 RCC in
children is higher than in adults as a percentage of
RCC [2], adult Xp11.2 RCC could still outnumber
pediatric Xp11.2 RCC due to RCC is more common in
adults (approximately 25,000 cases per year in the
United States) than in children (approximately 25 cases
per year in the United States) [23]. As previously men-
tioned, translocations are mainly located on the X
chromosome. Moreover, translocations might only
occur on the active X chromosome but not the Barr
body (inactive X chromosome) although females have
two X chromosomes. According to Sirchia [27], homo-
zygosity (two active X chromosome) can exist in nor-
mal somatic cell due to mutations occur during mitosis.
Thus, the possible explanation for gender-related differ-
ence existing in adults but not in children is that a




Fig. 4 Forrest plots and meta-analysis of studies showing 95 % confidence interval of Xp11.2 RCC in children as compared with adults. Clinical













Fig. 5 The survival function of patients. a Overall survival curve between male and female. b Overall survival curve between children and adult
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results from accumulation of mutations with age.
Nonetheless, more comprehensive and detailed studies
are required to confirm this speculation.
At diagnosis, metastases of Xp11.2 may occur in about
one-third of patients [28], who were older and predom-
inant in male [6]. Moreover, some studies showed that
Xp11.2 RCC has a higher degree of invasiveness and a
more rapid disease course in adult patients than children
[29, 30]. Nevertheless, a study reporting contradictory
data to that showed a case of children with bone metas-
tases at diagnosis and a very aggressive course [28]. In
our meta-analysis, the incidence of distant and lymph-
atic metastases and tumor stage between male and
female were comparable as well as between children
and adults. The important reason for the inconsisten-
cies may be explained by the differences of diagnostic
methods. Previously mentioned diagnosis was only
based on IHC assay, while this study adopted the com-
bined TFE3 IHC staining and FISH assay to exclude the
possibility of other subtypes of RCC.
The treatment for Xp11.2 RCC is still not well defined.
For Xp11.2 RCC including that with positive regional
lymph nodes, surgery is the optional treatment [26]
while NSS is an alternative treatment for patients with
tumors measuring < 7 cm [29]. Chemotherapy such as
sunitinib can be applied as well [31]. However, Xp11.2
has poorer prognosis no matter what treatment is ap-
plied [4, 32]. Recent studies reported that prognosis of
pediatric Xp11.2 RCC was better than that of adult
Xp11.2 RCC [30, 33, 34]. However, such conclusion was
based on small sample size without strict diagnosis. In
our meta-analysis, we grouped patients who have been
treated by RN or NSS to analyze the prognosis of RCC.
No statistically significant difference was observed in the
probability of survival between children and adults. In
addition, we analyzed prognosis in male and female by
survival curve and OS which showed no significant dif-
ference. Thus, this meta-analysis suggested that the
prognosis of Xp11.2 RCC between male and female is
comparable as well as between children and adults.
There are some limitations in this meta-analysis. The
sample size was still small and most of studies cannot
provide completely detailed information. In addition, the
number of existing high-quality studies is too small to
compare parameters about prognosis such as free pro-
gress survival. Further studies are required to solve these
problems.
Conclusion
This meta-analysis of the current evidence illustrate that
the female patients with Xp11.2 RCC in adults exhibit a
high incidence compared to the male, but not in chil-
dren. Comparable clinical characteristics including inci-
dence of distant and lymphatic metastases, tumor stage
and prognosis is presented between male and female as
well as between children and adults. Based on these re-
sults, the epidemiological information about gender dif-
ference in incidence of Xp11.2 RCC in adults is
provided. Further investigations on more comprehensive
and heterogeneous studies should be carried out to ex-
tend our results.
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